Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teijin Ltd.

www.teijin.com

Latest From EndoArt SA

EMBL Ventures Snags $55 Million In First Closing For New European VC Fund

Despite an ongoing European financial crisis, Germany's EMBL Ventures collects $55 million for its next venture fund to invest in European biotech.

BioPharmaceutical Europe

Devices Treat Obesity Patients without Options

Early intervention is the general rule for success in treating many diseases, but in obesity, patients have to be in bad shape before they're eligible for the most efficacious treatments, which are surgical interventions. Companies with minimally invasive--and anatomy sparing--devices hope to change that paradigm.

The Skinny on Obesity Products

The total obesity products market, including drugs and device, is projected to reach more than $1.6 billion by 2010, growing at a compound annual rate of 36.1%. Success in this arena will depend on whether emerging drugs and devices can live up their hype and deliver the results needed to achieve regulatory approval and marketplace acceptance.
BioPharmaceutical Medical Device

Deals Shaping the Medical Industry (3/07)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
See All

Company Information

  • Industry
  • Diversified
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Company Type
  • Top Japanese Pharma
  • Parent & Subsidiaries
  • Teijin Ltd.
  • Senior Management
  • Jun Suzuki, Pres. & CEO
  • Contact Info
  • Teijin Ltd.
    Phone: (81) 3 3506 4529
    2-1, Kasumigaseki 3-chome
    Chiyoda-ku
    Tokyo, 100-8585
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register